$8.29
0.20% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US92511W1080
Symbol
VRCA

Verrica Pharmaceuticals Inc Stock price

$8.30
+1.57 23.33% 1M
+1.82 28.03% 6M
-0.01 0.12% YTD
+1.27 18.13% 1Y
-19.20 69.82% 3Y
-112.10 93.11% 5Y
-166.70 95.26% 10Y
-166.70 95.26% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-0.01 0.12%
ISIN
US92511W1080
Symbol
VRCA
Industry

Key metrics

Basic
Market capitalization
$78.8m
Enterprise Value
$92.8m
Net debt
$14.0m
Cash
$21.1m
Shares outstanding
9.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.6 | 2.2
EV/Sales
3.0 | 2.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-18.2%
Return on Equity
776.7%
ROCE
-136.8%
ROIC
-
Debt/Equity
-2.1
Financials (TTM | estimate)
Revenue
$30.8m | $35.8m
EBITDA
$-15.8m | $-31.5m
EBIT
$-16.4m | $-10.5m
Net Income
$-26.0m | $-13.0m
Free Cash Flow
$-29.0m
Growth (TTM | estimate)
Revenue
234.7% | 373.0%
EBITDA
79.4% | 51.4%
EBIT
78.9% | 84.0%
Net Income
69.4% | 83.1%
Free Cash Flow
51.5%
Margin (TTM | estimate)
Gross
91.4%
EBITDA
-51.4% | -88.0%
EBIT
-53.2%
Net
-84.4% | -36.2%
Free Cash Flow
-93.9%
More
EPS
$-2.7
FCF per Share
$-3.1
Short interest
3.2%
Employees
71
Rev per Employee
$110.0k
Show more

Is Verrica Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Verrica Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

8x Buy
67%
4x Hold
33%

Analyst Opinions

12 Analysts have issued a Verrica Pharmaceuticals Inc forecast:

Buy
67%
Hold
33%

Financial data from Verrica Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
31 31
235% 235%
100%
- Direct Costs 2.67 2.67
12% 12%
9%
28 28
313% 313%
91%
- Selling and Administrative Expenses 37 37
44% 44%
120%
- Research and Development Expense 7.50 7.50
53% 53%
24%
-16 -16
79% 79%
-51%
- Depreciation and Amortization 0.56 0.56
39% 39%
2%
EBIT (Operating Income) EBIT -16 -16
79% 79%
-53%
Net Profit -26 -26
69% 69%
-84%

In millions USD.

Don't miss a Thing! We will send you all news about Verrica Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verrica Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
about one month ago
Proceeds will fully retire debt facility from OrbiMed and fund company operations, thereby extending expected cash runway into mid-2027 Financing anchored by Caligan Partners LP and PBM Capital, along with new and existing investors; Caligan Partners entitled to designate a new member to Verrica's Board of Directors WEST CHESTER, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals In...
Neutral
Seeking Alpha
about 2 months ago
Verrica Pharmaceuticals Inc. ( VRCA ) Q3 2025 Earnings Call November 17, 2025 8:30 AM EST Company Participants Jayson Rieger - President, CEO & Director John Kirby - Interim Chief Financial Officer Conference Call Participants Kevin Gardner Stacy Ku - TD Cowen, Research Division Yuchen Ding - Jefferies LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Brian Kemp Dol...
Neutral
GlobeNewsWire
about 2 months ago
–   Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH ® revenue and $10.7 million of license and collaboration revenue –
More Verrica Pharmaceuticals Inc News

Company Profile

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Head office United States
CEO Jayson Rieger
Employees 71
Founded 2013
Website verrica.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today